Mass Tort and Class Action Lawsuit Funding: How to Get Cash While Your Case Is Pending

When most people picture a personal injury lawsuit, they imagine one plaintiff against one defendant -- a car crash, a slip and fall, a surgical mistake. Mass torts and class actions are fundamentally different. They involve hundreds or thousands of people who have all been harmed by the same product, substance, or corporate conduct. Think of the veterans and family members sickened by contaminated water at Camp Lejeune, the residents who developed cancer after drinking PFAS-laden water near a military base or industrial facility, or the patients who needed emergency surgery to remove a defective hernia mesh implant that had perforated their tissue.

The legal term "mass tort" refers specifically to situations where each plaintiff has an individual claim with individual damages -- your injury is your own, and what you recover depends on the severity of your personal harm. This is distinct from a true class action, where a single lawsuit covers all members and any recovery is distributed equally or according to a formula. In practice, most large pharmaceutical and toxic exposure cases are handled as mass torts through a procedural mechanism called MDL (multidistrict litigation), which consolidates pretrial proceedings while preserving each plaintiff's individual claim. Understanding this distinction matters because it directly shapes how pre-settlement funding works in your situation.

The scale and complexity of these cases is exactly why the financial pressure on individual plaintiffs can be so severe. You are one person, dealing with a life-altering illness or injury, waiting on a legal process that involves thousands of other plaintiffs, armies of corporate defense attorneys, and years of pretrial proceedings before a single dollar changes hands. Pre-settlement funding was built for exactly this kind of gap between injury and justice.

The timeline for mass tort litigation is one of the hardest realities plaintiffs face. A typical car accident case might resolve in 12 to 24 months. Mass tort cases routinely take 5 to 15 years, and some asbestos cases have been working their way through the courts for decades. That is not because the legal system is broken. It is because proving corporate liability across thousands of individual claims, against defendants with virtually unlimited legal resources, is genuinely complex and time-consuming.

Before any settlement can be reached, attorneys on both sides must complete discovery across thousands of plaintiffs -- gathering medical records, exposure documentation, internal corporate communications, and testimony from scientific and medical experts. In MDL proceedings, the judge overseeing the consolidated cases will typically select a handful of "bellwether" cases to go to trial first. These are representative cases chosen to give both sides a preview of what juries think of the claims. Only after those trials conclude does global settlement negotiation typically begin in earnest, and the outcome of those trials heavily influences what the defendant is willing to pay.

Even after a global settlement is publicly announced, individual plaintiffs do not immediately receive checks. The settlement must be structured, a claims administrator must be appointed, each plaintiff's injuries must be evaluated and ranked against a settlement matrix, and government liens from Medicare and Medicaid must be resolved before net proceeds can be distributed. It is entirely common for plaintiffs to wait 12 to 24 months after a high-profile settlement announcement before any money arrives. If you joined a mass tort three years ago and a settlement was announced last month, you may still be well over a year from seeing funds.

This waiting period has real consequences. People who were working when they were injured may have been unable to return to work. Medical treatment for conditions like mesothelioma, cancer, or the complications of a defective device is expensive and ongoing. Bills accumulate. Retirement savings are depleted. The financial pressure becomes so intense that some plaintiffs accept inadequate settlement offers simply because they cannot afford to wait for a better one. Pre-settlement funding is specifically designed to relieve that pressure so you can wait for the outcome your case deserves.

Pre-settlement funding is available for a wide range of mass tort and class action cases. The key qualification is that you have an active lawsuit with a licensed attorney, documented exposure or product use, and a diagnosed injury or illness causally connected to the defendant's product or conduct. Here are the most common categories currently qualifying for funding:

Pharmaceutical drug mass torts involve medications that were approved and widely prescribed but later found to cause serious harm, including cancers, organ failure, birth defects, or cardiovascular events. Roundup (glyphosate), which has been linked to non-Hodgkin's lymphoma, is one of the largest active pharmaceutical-adjacent mass torts. Cases involving Zantac (ranitidine) and certain diabetes medications have involved tens of thousands of plaintiffs. If you took a medication and later developed a condition that has been scientifically associated with it, you may have a qualifying claim.

Toxic chemical exposure cases involve plaintiffs who developed illness from prolonged contact with dangerous substances in their water supply, workplace, or community. PFAS litigation -- involving so-called "forever chemicals" found in water supplies near military installations and manufacturing facilities -- has grown into one of the largest mass tort categories in the country. The Camp Lejeune Justice Act created a specific legal pathway for veterans and family members harmed by contaminated water at the North Carolina Marine Corps base between 1953 and 1987, and those cases are actively being funded.

Defective medical device cases involve implants or devices that caused harm after being placed in patients' bodies. Hernia mesh products that eroded and perforated surrounding tissue, metal-on-metal hip implants that released metallic particles into the bloodstream, and pelvic mesh products that caused chronic pain and injury are all active litigation areas. These cases involve plaintiffs who often need additional surgeries to address the damage caused by the device, creating both medical urgency and financial need.

Asbestos and mesothelioma cases are among the oldest and most active mass tort categories in U.S. courts. Asbestos exposure from construction materials, shipbuilding, automotive brakes, and industrial products causes mesothelioma, an aggressive cancer with a latency period of 20 to 50 years between exposure and diagnosis. Plaintiffs in these cases are typically older, often seriously ill, and have urgent financial and medical needs that make pre-settlement funding particularly valuable.

The mechanics of pre-settlement funding for a mass tort case are the same as for any personal injury case, with a few important nuances. You apply through a funding company, which reviews your individual claim with your attorney's cooperation. If approved, you receive a lump sum of cash -- typically a portion of the estimated value of your individual recovery. If your case resolves in your favor, the funding company is repaid directly from your settlement proceeds, before you receive your net distribution. If your case produces no recovery, you owe nothing.

What makes mass tort funding evaluation slightly different is the layered analysis required. Because mass tort cases involve hundreds or thousands of plaintiffs with varying injuries and varying quality of documentation, funders need to assess your individual claim within the context of the broader litigation. They will look at the nature and severity of your specific diagnosis, your documented exposure or product use history, the stage of the MDL process, and what attorneys actively involved in the litigation are projecting as reasonable individual settlement ranges. A plaintiff with a confirmed Camp Lejeune residency record and a current diagnosis of bladder cancer -- one of the conditions recognized under the Act -- is in a measurably different position than a plaintiff with less clearly documented exposure or a condition with a weaker causal link.

Amounts available through pre-settlement funding in mass tort cases vary widely depending on individual circumstances. That said, funders generally will not advance more than they believe a case is reasonably likely to recover, since they only get repaid if you do. This alignment of interest means that the funding company has a direct incentive to evaluate your case honestly and conservatively.

One critical point to understand: pre-settlement funding is not free. It carries a cost, typically expressed as a monthly or compound rate applied to the amount you receive. Because mass tort cases take longer than typical personal injury cases, the total cost of funding can be higher in absolute terms. A $10,000 advance held for four years will accumulate more fees than the same advance in a case that resolves in 18 months. For many mass tort plaintiffs, the alternative to that cost is losing their home, going without medical care, or accepting an inadequate settlement. But the cost is real and should factor into your decision. Discuss the full repayment projection with your attorney before signing any funding agreement.

If your case is part of a multidistrict litigation, you can still obtain pre-settlement funding. Understanding how MDL works will help you set realistic expectations about timing and the information funders will ask for.

MDL consolidates federal cases involving similar claims before a single federal judge, typically in the district where the most cases were filed or where the key events occurred. The MDL judge manages pretrial proceedings -- coordinating discovery across all plaintiffs, scheduling expert depositions, and selecting bellwether cases for trial -- but each underlying lawsuit remains your own. When the MDL phase concludes, either through a global settlement or a return of cases to their originating courts, your case is resolved based on your individual facts.

The bellwether trial process matters directly to your funding situation. When a handful of representative cases go to trial in the MDL, both sides watch the outcomes closely. Plaintiff victories in bellwether trials put enormous pressure on defendants, who face exposure across thousands of pending cases, and typically accelerate settlement talks. Defense victories may cause plaintiff attorneys to reassess settlement values and affect what funders are willing to advance. Experienced funding companies monitor MDL proceedings and factor bellwether outcomes into their case evaluations. If you are early in the MDL process with no bellwether trials yet scheduled, funders will typically be more conservative. If trials have already produced plaintiff verdicts and settlement talks are underway, the picture is clearer.

One practical note: if you are part of an MDL, your attorney may be part of a plaintiffs' steering committee or working with co-counsel who handles the day-to-day litigation. Make sure you know who is actually managing your case and that they understand and will cooperate with a funding arrangement. The funding company will need to communicate with whoever holds your file and will place a lien on your individual settlement proceeds, so clear communication among all parties is important.

Applying for pre-settlement funding in a mass tort case requires documentation that your attorney can typically help you gather. Here is what funding companies evaluate, and why each factor matters.

Liability strength is the first consideration. How clearly established is it that the defendant's product or conduct caused plaintiffs' harm? In well-developed mass torts like Roundup or Camp Lejeune, general liability has been extensively litigated, reducing uncertainty for funders. In newer or less-developed cases, funders may be more cautious because the science or the legal theories are still being tested in court.

Individual injury severity and documentation is the second factor. A confirmed diagnosis of a condition recognized as associated with the defendant's product -- supported by pathology reports, imaging, and treating physician records -- puts you in a substantially stronger position than someone with ambiguous or undiagnosed symptoms. Funders are evaluating the likely value of your individual claim, and the severity and certainty of your documented injury drives that estimate more than almost anything else.

Exposure or use documentation is equally important. For drug cases, prescription records and pharmacy fill history establish that you took the product. For toxic exposure cases, residency records near a contaminated site, employment records at an affected facility, or military service records placing you at an affected installation establish that you were there. For device cases, operative records showing implant placement establish that the product was used in your body. The stronger your paper trail, the easier the review process and the more confident the funder can be.

Stage of litigation matters because it affects the time horizon for repayment. A case in early MDL stages with no bellwether trials scheduled involves more uncertainty than a case where settlement negotiations are actively underway. Later-stage cases typically support larger advances because the timeline to resolution -- and thus the cost of the advance -- is more predictable. If your case is very early, you may still qualify for funding, but at a more conservative level.

Your attorney's experience is the final factor. A law firm with an active presence in the MDL proceedings, a track record in similar cases, and a clear understanding of the expected value of your individual claim gives funders confidence that your case is being well-managed. If your case has been referred to national mass tort co-counsel, make sure you have a clear point of contact and that they are aware of your funding application.

Several misconceptions lead mass tort plaintiffs to hesitate when considering pre-settlement funding, and it is worth addressing them directly.

"I'll owe money if I get less than expected." This is the most important misconception to correct. Pre-settlement funding is non-recourse. If the settlement amount allocated to your individual claim is less than the funding you received -- even if it is zero -- you do not make up the difference out of your own pocket. The funder absorbs that risk, which is why they evaluate claims carefully before approving anything. Your personal finances are not on the line.

"Funding will slow down my case or interfere with my attorney's strategy." Your funding company has no role in the litigation itself and no ability to direct how your case is handled. Your attorney continues working exactly as before. In fact, because funding companies want their advance repaid, they want your case to settle -- they have no incentive to delay or complicate proceedings. The concern about interference is understandable, but it does not reflect how the relationship actually works.

"My attorney won't cooperate." Most experienced personal injury and mass tort attorneys are familiar with pre-settlement funding and work with funding companies regularly. They are required to acknowledge the funding lien on your settlement proceeds and to handle repayment properly when your case resolves. If your attorney has concerns about funding, ask them to explain specifically why. Sometimes the concern is about a particular funding company's practices, which is a reasonable basis for recommending a different funder. Occasionally it reflects unfamiliarity with the process, which a direct conversation can resolve.

"I should wait until the global settlement is announced." This is a costly mistake many plaintiffs make. By the time a global settlement is announced, the financial pressure has often become acute, and plaintiffs are tempted -- or financially forced -- to accept less than their claim is worth just to get money quickly. Obtaining funding before that point gives you the stability to wait for a fair resolution rather than taking the first offer out of desperation. The whole point of pre-settlement funding is to give you the time your case needs.

If you are considering pre-settlement funding for a mass tort case, a few practical steps will make the process smoother and help you make an informed decision.

Start by talking to your attorney before you apply anywhere. Have a direct conversation about the funding process, what it costs, and whether it makes sense given the current stage of your case and the projected value of your individual claim. A good attorney will give you an honest assessment of your claim's strength and help you understand the realistic range of what you might recover. This conversation also prepares your attorney to cooperate with the funder's requests quickly, which speeds up the review process.

Gather your core documents. Medical records confirming your diagnosis, records documenting your exposure or product use, and any communications from your attorney about the status of your case all support your application. You do not need everything perfect on day one -- funding companies work with attorneys to gather what they need -- but having your key documents organized saves time and signals to the funder that your case is well-documented.

Apply through a reputable funder. Look for a company that is transparent about its rates and fees upfront, does not charge application fees or monthly maintenance fees stacked on top of the funding cost, and is willing to answer your questions in plain English. Read the funding agreement carefully -- or ask your attorney to review it -- before signing. Specifically, understand what your total repayment obligation would be under a few different timeline scenarios: if your case resolves in two years, in four years, in six years. That math should inform how much you ask for.

Finally, use funding for what it is designed to cover: essential expenses that you cannot meet while your case is pending. Housing, medical care, utilities, groceries, insurance premiums. Pre-settlement funding is not meant to be invested or used for discretionary purchases. The less you borrow, the less you owe when your case resolves and you are ready to move forward.

Mass tort and class action lawsuits represent some of the most consequential litigation in the country. They hold corporations accountable for products and practices that have harmed thousands of people who trusted that what they were given, drinking, or living near was safe. That accountability matters -- but the years it takes to achieve it impose a very real human cost on the people waiting for it.

Pre-settlement funding exists to make that wait survivable. It is not a loan, it does not appear on your credit report, and it costs you nothing if your case produces no recovery. It is a financial tool built specifically for the uncertainty of litigation, and mass tort cases -- with their multi-year MDL timelines, bellwether trials, global settlement announcements, and lengthy distribution processes -- are exactly the situation it was designed for.

If you are part of a mass tort or class action and struggling to cover your essential expenses while your case works its way through the legal system, Levalera can help. We work with experienced mass tort attorneys and evaluate individual claims on their own merits. You can apply in minutes, and our team will work directly with your attorney to determine whether funding makes sense for your specific situation -- with no obligation and no pressure to accept an offer that does not work for you.